<SEC-DOCUMENT>0001193125-25-028420.txt : 20250218
<SEC-HEADER>0001193125-25-028420.hdr.sgml : 20250218
<ACCEPTANCE-DATETIME>20250218130336
ACCESSION NUMBER:		0001193125-25-028420
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250218
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250218
DATE AS OF CHANGE:		20250218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cabaletta Bio, Inc.
		CENTRAL INDEX KEY:			0001759138
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39103
		FILM NUMBER:		25633993

	BUSINESS ADDRESS:	
		STREET 1:		2929 ARCH STREET
		STREET 2:		SUITE 600
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(267) 759-3100

	MAIL ADDRESS:	
		STREET 1:		2929 ARCH STREET
		STREET 2:		SUITE 600
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>d925657d8ka.htm
<DESCRIPTION>8-K/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:caba="http://www.cabalettabio.com/20250218" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K/A</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-282">true</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-02-18_to_2025-02-18">0001759138</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="caba-20250218.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-02-18_to_2025-02-18"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-02-18</xbrli:startDate> <xbrli:endDate>2025-02-18</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-293">8-K/A</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Amendment No.&#160;1)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-02-18_to_2025-02-18" format="ixt:datemonthdayyearen" id="ixv-294">February&#160;18, 2025</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-295">CABALETTA BIO, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in its Charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-02-18_to_2025-02-18" format="ixt-sec:stateprovnameen" id="ixv-296">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-297">001-39103</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-298">82-1685768</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-299">2929 Arch Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-300">Suite 600</ix:nonNumeric>,</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-301">Philadelphia</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-302">PA</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-303">19104</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-304">(267)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-305">759-3100</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-02-18_to_2025-02-18" format="ixt-sec:boolballotbox" id="ixv-306">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-02-18_to_2025-02-18" format="ixt-sec:boolballotbox" id="ixv-307">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-02-18_to_2025-02-18" format="ixt-sec:boolballotbox" id="ixv-308">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-02-18_to_2025-02-18" format="ixt-sec:boolballotbox" id="ixv-309">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of Each Class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of Each Exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on Which Registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-310">Common Stock, par value $0.00001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-311">CABA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-02-18_to_2025-02-18" format="ixt-sec:exchnameen" id="ixv-312">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-02-18_to_2025-02-18" format="ixt-sec:boolballotbox" id="ixv-313">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Explanatory Note </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="dei:AmendmentDescription" contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-168">Cabaletta Bio, Inc. (the &#8220;Company&#8221; or &#8220;Cabaletta&#8221;) filed a Current Report on Form <span style="white-space:nowrap">8-K</span> on February&#160;18, 2025 in connection with a press release announcing new and updated clinical data from the first 10 patients dosed with resecabtagene autoleucel (rese-cel, formerly referred to as <span style="white-space:nowrap">CABA-201)</span> across the RESET clinical development program (the &#8220;Original <span style="white-space:nowrap">8-K&#8221;).</span> This Amendment No.&#160;1 (&#8220;Amendment No.&#160;1&#8221;) to the Original <span style="white-space:nowrap">8-K</span> is being filed to clarify that as of the data <span style="white-space:nowrap">cut-off</span> date of January&#160;8, 2025, in the RESET-Myositis trial, the first adult dermatomyositis patient was off all immunosuppressants and tapering steroids, to revise other similar statements, and to note that a revised copy of the corporate presentation has been posted to the Company&#8217;s website and a copy of the revised press release has been furnished herewith to reflect the same, and no changes to the other information filed with the Original Form <span style="white-space:nowrap">8-K</span> have been made.</ix:nonNumeric> </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;18, 2025, the Company filed Amendment No.&#160;1. A revised copy of the corporate presentation has been posted to the Company&#8217;s website and a copy of the revised press release is attached hereto as Exhibit 99.1, and no changes to the other information filed with the Original Form <span style="white-space:nowrap">8-K</span> have been made. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained in Item 7.01 of this Current Report on Form <span style="white-space:nowrap">8-K,</span> including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be &#8220;filed&#8221; for the purposes of Section&#160;18 of the Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;18, 2025, the Company issued a revised press release to clarify that as of the data <span style="white-space:nowrap">cut-off</span> date of January&#160;8, 2025, in the RESET-Myositis trial, the first adult dermatomyositis patient was off all immunosuppressants and tapering steroids. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:94%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d925657dex991.htm">Press Release issued by the registrant on February&#160;18, 2025, furnished herewith. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL Document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">CABALETTA BIO, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: February&#160;18, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Steven Nichtberger</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Steven Nichtberger, M.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d925657dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g925657g0218215506412.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cabaletta Bio Announces Updated Clinical Data </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Demonstrating Deepening Clinical Responses across </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Multiple Indications with Rese-cel at February Scientific </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Meetings </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#150; Clinical
efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these patients discontinued
all immunosuppressants and are off or tapering steroids as of the latest <FONT STYLE="white-space:nowrap">follow-up</FONT> &#150; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#150; Safety profile continues to suggest favorable risk-benefit in the first 10 patients dosed; 90% of patients experienced either no CRS
or Grade 1 CRS (fever) and 90% of patients experienced no ICANS &#150; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#150; Deep B cell depletion observed in all patients after
rese-cel infusion with a transitional na&iuml;ve B cell phenotype upon repopulation; tissue-resident B cell elimination confirmed by a lymph node biopsy in a scleroderma patient &#150; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#150; 50 clinical sites in the U.S. and Europe actively recruiting with 26 patients enrolled across the RESET<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> clinical development program as of February&nbsp;13, 2025 &#150; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PHILADELPHIA, Feb. 18,
2025</B> &#151; Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced
new and updated clinical data from the first 10 patients dosed with resecabtagene autoleucel (rese-cel, formerly referred to as <FONT STYLE="white-space:nowrap">CABA-201)</FONT> across the RESET clinical development program. These data were
presented by Aimee Payne, M.D., Ph.D., <FONT STYLE="white-space:nowrap">Co-founder</FONT> of and Scientific Advisory Board <FONT STYLE="white-space:nowrap">Co-chair</FONT> at Cabaletta Bio in the &#145;Science Breakthroughs&#146; session at the 2025
annual meeting of the American Association for the Advancement of Science, which was held in Boston, MA from February <FONT STYLE="white-space:nowrap">13-15,</FONT> 2025, and are being presented by Samik Basu, M.D., Chief Scientific Officer at
Cabaletta Bio at the 5th International Conference on Lymphocyte Engineering, which is being held in Munich, Germany from February <FONT STYLE="white-space:nowrap">20-22,</FONT> 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The expanding clinical experience with rese-cel underscores its potential to provide compelling clinical responses without the need for
immunosuppressants or steroids in patients with active, refractory autoimmune disease. With patients across the ongoing myositis, lupus and systemic sclerosis trials achieving DORIS remission in SLE, complete renal response in LN, and major TIS
improvement in dermatomyositis, all while off all immunosuppressants and off or tapering steroids, we believe rese-cel has the potential to transform the lives of patients with autoimmune disease,&#148; said David J. Chang, M.D., Chief Medical
Officer of Cabaletta. &#147;We intend to include these data when we meet with the FDA to align on registrational trial designs in the first half of 2025. We believe our expanding footprint of clinical sites in the US and Europe has facilitated our
ability to accelerate the pace of enrollment and dosing across the RESET program. With an average of one patient enrolling per week since November, we anticipate that we will generate sufficient data to further clarify rese-cel&#146;s profile across
multiple indications this year to rapidly deliver its therapeutic potential for autoimmune patients.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cabaletta is currently evaluating rese-cel in the RESET (REstoring SElf-Tolerance) clinical development
program, which includes six company-sponsored Phase 1/2 clinical trials with disease-specific cohorts, spanning the therapeutic areas of rheumatology, neurology and dermatology. All cohorts are evaluating a weight-based single infusion of rese-cel
following a preconditioning regimen of fludarabine and cyclophosphamide, except for the <FONT STYLE="white-space:nowrap">RESET-PV</FONT><SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> trial, which is evaluating weight-based dosing of
rese-cel without preconditioning. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New and Updated Clinical Data Summary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the data <FONT STYLE="white-space:nowrap">cut-off</FONT> date of January&nbsp;8, 2025, 10 patients had been dosed with rese-cel across the RESET-Myositis<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, <FONT STYLE="white-space:nowrap">RESET-SLE</FONT><SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> and RESET-SSc<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> trials with
sufficient <FONT STYLE="white-space:nowrap">follow-up</FONT> to be evaluable, providing the following key insights: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In the RESET-Myositis trial, the first adult dermatomyositis patient maintained a major total improvement score
(TIS) improvement at 3 months post-infusion, off all immunosuppressants and tapering steroids, showing potential for achieving drug-free remission in patients with refractory myositis. In addition, initial clinical responses in the first 2
immune-mediated necrotizing myopathy (IMNM) patients continued to show more gradual improvement, consistent with published academic data, suggesting response kinetics may differ among myositis subtypes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In the <FONT STYLE="white-space:nowrap">RESET-SLE</FONT> trial, 3 out of 4 patients in the <FONT
STYLE="white-space:nowrap">non-renal</FONT> systemic lupus erythematosus (SLE) cohort achieved DORIS (definition of remission in SLE) remission as of the most recent <FONT STYLE="white-space:nowrap">follow-up</FONT> visit. The first patient dosed
with rese-cel in the lupus nephritis (LN) cohort achieved a complete renal response (CRR). All 6 SLE and LN patients dosed, including these patients, demonstrated clinical responses off all immunosuppressants and steroids as of the data <FONT
STYLE="white-space:nowrap">cut-off</FONT> date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In the RESET-SSc trial, the first patient dosed with rese-cel in the severe skin cohort continued to demonstrate
clinically meaningful skin improvements across an increasing number of body areas at 3 months post-infusion, in addition to improvement in lung function, after discontinuing all disease-specific therapies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rese-cel consistently demonstrated deep depletion of B cells in the periphery within the first month of infusion.
Tissue resident depletion consistent with the deep B cell depletion in circulation was confirmed by a lymph node biopsy in a systemic sclerosis patient. B cell repopulation has typically started around 2 months post-infusion and exhibited a
transitional na&iuml;ve phenotype, reflecting the production of new B cells after deep systemic depletion. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Across the first 10 patients dosed with rese-cel with at least one month of
<FONT STYLE="white-space:nowrap">follow-up,</FONT> 90% experienced either no cytokine release syndrome (CRS) or grade 1 CRS (fever) and 90% experienced no immune effector cell-associated neurotoxicity syndrome. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional information can be accessed on the website of each scientific meeting. Presentation materials
will be made available on the Posters&nbsp;&amp; Publications section of the Company&#146;s website following each event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About rese-cel (formerly
referred to as <FONT STYLE="white-space:nowrap">CABA-201)</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rese-cel is a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">4-1BB-containing</FONT></FONT> fully human <FONT STYLE="white-space:nowrap">CD19-CAR</FONT> T cell investigational therapy for patients with autoimmune diseases where B cells
contribute to the initiation and/or maintenance of disease. Following a <FONT STYLE="white-space:nowrap">one-time</FONT> infusion of a weight-based dose, rese-cel is designed to transiently and deeply deplete all CD19-positive cells in both the
peripheral circulation and within tissues. This approach has the potential to reset the immune system and result in profound clinical responses without chronic therapy requirements in patients. Cabaletta is currently evaluating rese-cel in the RESET<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> (REstoring SElf-Tolerance) clinical development program which includes multiple disease-specific, company-sponsored clinical trials across expanding portfolios of autoimmune diseases in a broad
range of therapeutic areas, including rheumatology, neurology and dermatology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cabaletta Bio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed
specifically for patients with autoimmune diseases. The CABA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell
therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel,
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">4-1BB-containing</FONT></FONT> fully human <FONT STYLE="white-space:nowrap">CD19-CAR</FONT> T cell investigational therapy. Rese-cel is currently being evaluated with a single
weight-based dosing regimen across the RESET<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology.
Cabaletta Bio&#146;s headquarters and labs are located in Philadelphia, PA. For more information, please visit <U>www.cabalettabio.com</U> and connect with us on LinkedIn. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
&#147;forward-looking statements&#148; of Cabaletta Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, express or implied statements regarding: Cabaletta&#146;s business plans
and objectives as a whole; Cabaletta&#146;s ability to realize its vision of launching the first curative targeted cell therapy designed specifically for patients with autoimmune diseases; Cabaletta&#146;s ability to successfully complete research
and further development and commercialization of its drug candidates in current or future indications, including the timing and results of Cabaletta&#146;s clinical trials and its ability to conduct and complete clinical trials; expectation that
clinical results will support rese-cel&#146;s safety and activity profile; statements regarding the timing of interactions with regulatory authorities, including such authorities&#146; review of safety information from Cabaletta&#146;s ongoing
clinical trials and potential registrational pathway for rese-cel; Cabaletta&#146;s expectations around the potential success and therapeutic benefits of rese-cel, including its belief that rese-cel has the potential to reset the immune system and
result in profound clinical responses without chronic therapy requirements in patients; the Company&#146;s advancement of separate Phase 1/2 clinical trials of rese-cel in patients with SLE, myositis, SSc and gMG and advancement of the <FONT
STYLE="white-space:nowrap">RESET-PV</FONT> and <FONT STYLE="white-space:nowrap">RESET-MS</FONT> trials, including updates related to status, safety data, efficiency of clinical trial design and timing of data read-outs or otherwise; the clinical
significance of the clinical data <FONT STYLE="white-space:nowrap">read-out</FONT> at upcoming scientific meetings; Cabaletta&#146;s belief that its expanding clinical experience with rese-cel underscores its potential to provide compelling clinical
responses </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
without the need for immunosuppressants or steroids in patients with active, refractory autoimmune disease, as well as its belief that rese-cel has the potential to transform the disease outcome
and the lives of patients with autoimmune disease; and Cabaletta&#146;s belief that its growing number of sites will allow it to continue accelerating the pace of enrollment and dosing across the RESET program, further enabling it to evaluate the
emerging clinical profile of rese-cel and its therapeutic potential for autoimmune patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this press release are
based on management&#146;s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to regulatory filings and potential clearance; the risk that signs of biologic activity or persistence may not inform long-term results;
Cabaletta&#146;s ability to demonstrate sufficient evidence of safety, efficacy and tolerability in its preclinical studies and clinical trials of rese-cel; the risk that the results observed with the similarly-designed construct employed in
academic publications, including due to the dosing regimen, are not indicative of the results we seek to achieve with rese-cel; risks that modifications to trial design or approach may not have the intended benefits and that the trial design may
need to be further modified; risks related to clinical trial site activation, delays in enrollment generally or enrollment rates that are lower than expected; delays related to assessment of clinical trial results; risks related to unexpected safety
or efficacy data observed during clinical studies; risks related to volatile market and economic conditions and public health crises; Cabaletta&#146;s ability to retain and recognize the intended incentives conferred by Orphan Drug Designation and
Fast Track Designation or other designations for its product candidates, as applicable; risks related to Cabaletta&#146;s ability to protect and maintain its intellectual property position; risks related to fostering and maintaining successful
relationships with Cabaletta&#146;s collaboration and manufacturing partners; uncertainties related to the initiation and conduct of studies and other development requirements for its product candidates; the risk that any one or more of
Cabaletta&#146;s product candidates will not be successfully developed and/or commercialized; and the risk that the initial or interim results of preclinical studies or clinical studies will not be predictive of future results in connection with
future studies. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Cabaletta&#146;s actual results to differ from those contained in the forward-looking statements, see the section
entitled &#147;Risk Factors&#148; in Cabaletta&#146;s most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> as well as discussions of potential risks, uncertainties, and other important factors in Cabaletta&#146;s other
subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Cabaletta undertakes no duty to update this information unless required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anup Marda </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investors@cabalettabio.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>caba-20250218.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 2/18/2025 11:01:22 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:caba="http://www.cabalettabio.com/20250218"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.cabalettabio.com/20250218"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="caba-20250218_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="caba-20250218_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>caba-20250218_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 2/18/2025 11:01:22 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:type="locator" xlink:label="dei_AmendmentDescription" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Description</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Description</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>caba-20250218_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 2/18/2025 11:01:22 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="caba-20250218.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:type="locator" xlink:label="dei_AmendmentDescription" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentDescription" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g925657g0218215506412.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g925657g0218215506412.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  = -<# 2(  A$! Q$!_\0
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.0!L*-JA?08HI:* /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45864173287456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 18, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001759138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 18,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CABALETTA BIO, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1685768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2929 Arch Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">759-3100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CABA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Cabaletta Bio, Inc. (the &#8220;Company&#8221; or &#8220;Cabaletta&#8221;) filed a Current Report on Form 8-K on February&#160;18, 2025 in connection with a press release announcing new and updated clinical data from the first 10 patients dosed with resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) across the RESET clinical development program (the &#8220;Original 8-K&#8221;). This Amendment No.&#160;1 (&#8220;Amendment No.&#160;1&#8221;) to the Original 8-K is being filed to clarify that as of the data cut-off date of January&#160;8, 2025, in the RESET-Myositis trial, the first adult dermatomyositis patient was off all immunosuppressants and tapering steroids, to revise other similar statements, and to note that a revised copy of the corporate presentation has been posted to the Company&#8217;s website and a copy of the revised press release has been furnished herewith to reflect the same, and no changes to the other information filed with the Original Form 8-K have been made.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M >@= 7R"59^XHR[Q'._R_?0!<JL(>A5!S^"='\&;\@T(\O=D)97 $/[3Q*A
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M[SV^^1%-UW"TD6P!>IXL'B:_VSC50N^=)/2/"8BU]M(OB* BG84931O/)BV
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ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
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M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ <FA26IE<G",0!@  G"<  !,
M             ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" !R:%):+ I3;6X&  "T%0  &               @($."   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ <FA26I^@&_"Q @  X@P   T
M             ( !L@X  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !R:%):
MEXJ[',     3 @  "P              @ &.$0  7W)E;',O+G)E;'-02P$"
M% ,4    " !R:%):'#AEZC\!   \ @  #P              @ %W$@  >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ <FA26B0>FZ*M    ^ $  !H
M         ( !XQ,  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ <FA26F60>9(9 0  SP,  !,              ( !R!0  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  $A8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d925657d8ka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>caba-20250218.xsd</File>
    <File>caba-20250218_lab.xml</File>
    <File>caba-20250218_pre.xml</File>
    <File doctype="8-K/A" isOnlyDei="true" original="d925657d8ka.htm">d925657d8ka.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d925657d8ka.htm": {
   "nsprefix": "caba",
   "nsuri": "http://www.cabalettabio.com/20250218",
   "dts": {
    "schema": {
     "local": [
      "caba-20250218.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "caba-20250218_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "caba-20250218_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d925657d8ka.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-02-18_to_2025-02-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d925657d8ka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-02-18_to_2025-02-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d925657d8ka.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "terseLabel": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.cabalettabio.com//20250218/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-25-028420-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-028420-xbrl.zip
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MHP^%M4=<7V)[##ML_FRC]"5G*3-,C._PQU@Q:^TP9E7*^@*K<NMH^;.9\JC
M#CG NZ7B.8A]%JT>1J/#I\67(M27WDNNUQ1/_=E#V>I-3^L9J*]G61''&Z(5
MWAU7?S96^I#.K,4X&0Z8X0??2N[JZLMMUZOCY,_NR4!1>V*NO\R'\N"?NRU1
M?0EM&75X_-D?<4/L>I%.J!C#,8];J[7UA57MUS'S;1_D.@<UQK'W0<FYF>#\
M/J7BR"-#>T+4E^"+MAU(?[9"/A];NP*=*C;=/3-YP-F\DK:^Z*K].F;_PQ;)
M1;23DULLL(>65U?L/WL$%TO^ 5!+ P04    " !R:%):D3GF6@<1  !4<
M#P   &0Y,C4V-3=D.&MA+FAT;>T=:W/B1O*[?\44>TGL*EX"; /V<N7%;([+
MKNT"IY*Z+ZF1-%B3%1IE-#)PO_ZZ1P_$RV >MO=B5^T:,:^>?G=/:WSYS_'0
M)8],!EQX'W\RBN6?"/,L87/OX>-/5_UVM_O3/UM'EXZ";M#5"YHVXQ]SCE)^
MLU0:F](M!LPJ/HC'$C24*N5*+1=W#(."FO@L2'L/:& 6A7PH)2TSW3WA>>$P
M[3P:C8IZ>AQ@*UG"$27H5(!>3'(K&3=VN?=M9MBHJ@<9C4:CI%N3K@L]TP4J
MY7*UA,TF#5C2W:(FG>F.7[A,*6IR4;3$$.$_+5>,>@I+P)=! K,;I=^_?NE;
M#AO2 O<"13TK72=4<B54C1*T)AUY(&H5X_R)+<0]T@'C57T-Z.O!AMGOGWI?
MIMW5\O[3KB4EJ1<,A!Q2!2R#,YT6RI5"Y2PS20%88F:BA$76S5,O5(T4E[ X
M?VJK<UC$5GN.->/.9Z6H,>ZZFEF0S7/([HS:\$MQY;)6O?!+Z>JR%#T<70Z9
MH@0G*+"_0O[X,=<6GF*>*MP#@^:(%3U]S"DV5B4]80E&E:(I"2&7IK GK4N;
M/Y) 35SV,6?SP'?I!"6 Y5KDDH^;V)O)^#.W;>9%GZ'+3<3^Q*-#',MX\VK(
M/!O^J<\N?8@A&*L>&T!S*#5^_T!.13H9]3^4R#SE"+<_YOCXL5"I5W(M)4-V
M69I9:&%A'/ O#=,?L/H?'0\P,VG#\I*Z7<]FXU_8))<!;T6'YX'9*H,,G9\V
MC&I]$;[2')8D&S ):HP%\(Q2W0RTY,%:AU0:>B544Q]S 1_Z;OJ=(W&3J#T*
MB<8HC@,[::;2D@(98?TBI7BW,SO4SX$(9?2H!:<9HU=3:P/T)L.8)E;ZR&W\
M8L"9)!J%;*E8M[N_S!)H?C!"O71^'R@H[/01)%JJ:ZI8:PI;,G+:-H757M$W
M:4F73=<IS6 GQ>84>Z6L])5 2N%71E9Q5(&Z_,%K6K 7)G.S[2-N*Z=9+YYR
M[R+3UV4#=3&D\H%[!?S<)#14(OE&\@<G_@JG\Y/)4%D6'*9;P33[Z11*^,W,
MHRF4$D/]C2DD@)Y\8_AC$@B7V^1#6?_D6C]^,,[*%Y<E?]5"U?4+5;9>*#-M
M#28ABQL@ R!-(>#_94VCGCX/Z)"[D^8]'[* W+ 1Z8DA]2YTVRB"VQ2N?;&$
M/+_>=.\[UZ1_?W7?Z:\&I_Q"X/0[[5][W?MNIT^N;JY)Y_?VOZYN?NZ0]NW7
MK]U^OWM[LQ.,E7W ^!L-''  E?#RY+K8+I)*^;36F(-KNFA] \:<Y8=U K64
M,<^V8LQB&;K-\N9%)*05XX?%S6\HI-/-)#IB&;WJ+\13GV][7\EEX%,O54,.
M5ZP WU@,3.5(4C_76ND_7 LK1/<AX\!LX3XTJKG$59JUSY<EA*SU^FQ]G#I*
MY$84(Q(:)^]L?0"VW@N]0%'V.C?WI->YN^W=OS[_W(4R""EPCQ*DSRP4C)B)
MJD1(8IP>V_/<] I0B@&Y=Q@"&$JN.(SOC"V'>@^,7%F*0+/1J-96P_E2U%VK
MCNZTS]:)7+EGZZ4HM$3=I)HV3#"$X8Y-)Q-&P7'.ZJT:*%!FRI#*24S.>I[@
M5(N*[+5IBYA "O:8+Z0BQ\DS[,D%2BO"'E&[2=W,%KCQ7;?M0;=5:ON@Y.IH
M/@J7>^R!!Y@C43?0LH-5/@4]>O7IZDOG_OZ*?.K>YDGWIEU<$D/OP-OEO5CG
MSIB"?D)$1"R>((#0@/1]9F$D:1/N$:X"TG8@&F3RG<,WX_ =\')TJ:CI,F(Q
MUT6'$C/#N7)./_O4MI/G>*5XIY9P7>H'K)E\>)I!R"R $2Z,<OF'&'/-<@QE
MLYR$R0"7U/_;L[%WM?8#IDFR#8],*FY1-T9JM-'Y3O'HRF:C$Q 7>F>GN2S%
M(,JDU:</K&!*1K]A%IC;K$D?!3#!QM@Q-'F>@@^HNM3<9L.#>7E\PAI'ZJCK
M64*"4=%ZIZ_ [+1%Z"DY:0M[)]N,J6),[2CF2_&(R\X:YS,P>LRE(S#:*^,*
M96]"[I2GUW3?$G];1U\1@C]SET&;"4MMK^O/,0MG%*H-HUQ=B:W_(Z3=TW$W
MSC%:&DL[8[ .,2Q\=U8_/3];2#0O0>$!)+R^I8!O:[WWDH$XUCH!HR"A'";)
MGQ![!#;7,=*S7 OC ,"!-\&S^NLD,I$O(@&O2Y6V& YY$+P%(J""(Y%\_GWP
MWRWVBOTBZ0Q]5TR8?'4BS&I+S()-::%5&?R'SMYWZCKJ0&07W_&TO!?OKU9_
M->\OAF^/DK"?Z&Z-);^R;<F"(/[U!0(L8P<KWLBU*HU*@UQ)RR%])1E3\[8\
MORX 7X2HLC5$53P/ZX?@WY"S<GD!E%W4PDM2IPT?;^6]&'D[8,+(M>X<[E*;
MN;[#Z;9TT?[&K;R#H('K(I"M :H 0$O.+/9OH5:+YFZQ68R1.P%AE/L?[F\5
MDDWQ4<VU# @@:D^%6V_([5V#N^,8.YA2\B6P"O>I2]B86:'BCYAI FO(@I,W
M%1<= Q4)DO%D >E+#/3S<O>'U1>H(JZ "W;DP1K@H')V?K*8IMPZ8OPB@"IW
MCO!V#;.KY=-<Z_RT4:@:B[I\#V>=^_$\I^G3'S_4*\;Y14 4<YF/""">QD >
MHR(W1"^,4* 9($1SW X'0WMAKANAR)7ONR!&P.FOC\K/0@)QX\2TU,DK>*21
M7@$D#DATO 8Z $T1<6F0',&\IZ</<;B\CLMRK;;#K&]$.8Q0WY<"%#]F)TPQ
M)B9SQ0AIAHU(V?4JI5[X)19K,N N2@L/0'04\VR@N1) ]F'H*NHQ$0;NA 2@
M28+!1*\0#Q FH"N*N42TM)P>;X0P#_"3-TG:!A#WB!&.PYPHQ_ ]:*[DI-JV
M4=E>HZXTU)J&7XMQWEP<N)$'D5L:8/UP\;2A159\PAC\)KD"^F%Z)/3B:#C8
M.8UM"N&:%&BG@-.R!N,,\=\XK]4N%NW%\QR(:%\9/B"SI"<[:^B%Q6)< 7*R
MR")^IABB%P([U2JG,2NKV?(#K#HX-LY)^W./5*KE(G1\3M;AG;^?S]]]4-T6
M8-][^ J*#[2?>SCF/O^>F7N**)@ZPM0B9Z^U$$:-%HQ*8B2F0C!3>).(P-K9
M*K5R,9KQ).-.ODO+P:3E3C*T!%A.K\L@T;#+V\%@BR!A8ZFI?\]2LY:% :,%
M*X/21#36V9 -),TN5([-D_W*6C3GN[2]AK1U@R!D\D5DKO$N<UO)7)45:L?6
M?F4NGG-CF=MWA)CQ3Z-0C$D(YOR5%;ZH()+X#':[.AQ[\X=D[_55STM#;Y ;
M6;&#!=[?Z5CN$.?!]_A.*[)UAUH.:;LT"/9R\K$USMX<@B1% ;PT9:G5GPRA
MVW&PG_*%5T'1(?*C-W'!KF:AQ"*\>J6#\,AO#@>(>JEVG[4Q;Z4L<V4('QFH
MB5$QM91N?UYA@+>''A>@I*^$]2U/?"K)(W5#1OY1+B*K&<3'-WR=I566+W,B
MM@H/L01&PK<#$HRH#OZM;2\A<R(X6U7[SWO #":;+Z6M&A509^"]W-# IG^1
MGUT!3C)X.2[X.>0KE=\6BR1>U"/K>C8ZJ8R8$V+I_#W,^(V,'*8K"N>2YCP@
MX&6"HXN+/I '*4;*05_7QT0Z#8C-!MR+WA>(TI/ET\1_F\M-1F]$5<DQDOC\
M0J<HD\ZP#-#%QS<-\.QG0X>Y8A;2;-#BFLM>QUH_:0(=.L\+\V? +![T "_7
MZBQ'^8\?ZD8# JNG2Q62P3_KL>UHZ,$"/J/Z1,!W4"1U!T]P)YZ[+F5UOG T
MY  C:P$%1O:$#DO"@.E>@*_X  HO4N'Z;"FZY0#QH]=R)[CXB,/2*!0>P <M
MDCWR ,:!>%#/PH0GM2PLYL?.>*6*3:4=1$=/]I,Q4?68IC%1EJF+,3.DN-_;
M&>C_V\T(T4%H?!QZ=+24(0TV7&!(_"KCLY@,2 X^BSNBDR 7O<QU=.FD[@W$
MB$(V/S3TST6R&W^<C0,MEU&)UL[1$=?1FO/F_=YY<?2ZQ8F=L>]2CRHA)^1&
M@%RN5@_1>YR[ZH?U5_E<L\"2W$=IV]KI,<[JX/0D=U:13USD2=>SBN08)1;K
M0BKEBW:JORL5XP(51-*0#(R;3O P&_0!)>U02GS--'X+%13/LP_2<<S2=V[1
M7L-VO4C1Q,H+E!&6<$E0A134'_4\T%>8*-$Z#306"7U\Q]<F%L@K>F,$'BD9
M2#&,C^%EH(A1!J$!$^PI< \$ZD ]/<S-+&HJD">/:89T66@QEQQC2P$^Y>.B
M#W="],4[,CKW!^6\=L_H<Q8J92/-GE%+"M@+0M7K]#OW&9#9(W.%K^\G .W[
M(.EPAE*W(#*@L]V-$)T0K9BL>X].PK(+$-#OT?,O:TQI#]M%4)X%0[(T+&PR
MI%;$0#"5Y5+)=8D$U:]WQD9$$VWMS%:H"F(P2&:WXW>@_TV]*3O%W(2F=HKJ
MPM>)0$L)V,>#OGR&-:@=N@HH@(Z%&";=8FXA(PTBV'37)1RSJ2((?<V3%'D)
M&5!1-+[:@C()H6.0QWU&MC9^)R;@H PH*F5\'1VY,!\-%6C;68R,U#Y;PD\K
M0I*75YB6!!@:U9*@>V""ET]\$:@(L]@[(]*Z\&O$S !KCW$Q.C-OLM:L?*73
M#D+I\<"!#@ _T\*B-S70,0-.$(#FBG;AB;@,*DC B';-O?22MYC^T3Q99GJV
M^G#H(XM '%*;+7^;^2AK7(_(T=_;OLX=/'VZ[5UW>H7V[9<O5W?]3C/Y\)8/
MG@QCPY.GIXMKNR!\*!IEX^*\6#8V+?Q]\1.@IQR7:/4>>PC=2+(^7Y-K'E@N
M*"89N2^;QNYG^_!G;E>9\WQ6(<7RO\S.%,G5&U!\F%0 A\=*-%YDXSMCAYM<
MD4:C:+R^KCNX;XHYHNQ&T/FD22H%A8>@V*1YAQV<P7SJ(*1UR%E<S],BGW$D
M4L.$Y @<-,P8'YO@0S"PK9HCS-1STK1(/%R,CI$B$-<"]S#M?,S&M?5E06V2
MJ<DC2]!A%'MGW;-LY\1MRJ=OQ([0#PA"\T]M.2.F<3DUN1LEA?2*8/^#V/%=
MV-?T#598UXP=43SK1;+$PH6H65F"%Z>YLO!K\.8WFB=L;#%?^V41!"9F&[2D
M8'4K4XA"8&L (HBNY;!FH0E"RXG!66#7#"MN?5+Z;L,R-JS^?=NP6ZTX.WAM
M45!\LX:+8Y&*G7'.9^W&WR.B*;Z[U>]N]28JJ?%]JZ3/:6*\GT;J6B)BY^3E
M]=0"T+G6L7V2PO.$C:T<N!II/PR_03G2T5%4D*1_V:7X]R8E1-45)42-6EI"
M%$_^PM4 RRP!^KW//)+>_& :9)B2Z"YRNU$Y/3L]M]FXT3"*CAKJ^D$P:;TT
M%-(6SYS,'TFMS-SFEZ2+4%+HJJ*+#+X6T)6\O@8-I94M$)H@CWH?<Y77O&QK
MZ1$POC]],#*V!7Q+[F![I(MVC5KZ7>9K=#;T/2O';&@RVXX#T-ACZ.H_OD#P
MKR^0Y(Y-S \GQ#E*]=B[C7\S1U/][L\W5_>_]CH'C_NSM]M&,O]7R&5L_C:K
M8IB-+9><98-/.B$6#=&%UMF#Z#79.%H/8./0(*(;'DT&P><@T4 ZK(TZY+5Z
M"3T8I.<#.CE"PB[MIZ+-[]82SMN^N6K\4[1BFUO#E5?6;#C-BG+</0%Q^HHF
M>?G^]G'EQT'FG!J_ZEK??.D%L$_=YK&!:4:!6F&;==.L<=YOMU>\62FZ@[FY
MP@<ZS)4Q^^4?[4%\FC0/!.LSRW[7%,L\TX:5@A($;7@)-KGAEJ-,)A^B:]=>
MK_#W.],KAYBSM4B3//E:O"Z^4^4UJ8(1G_X;33J[T78X&X!;E]R,=*MO1I*;
MQ >7I>AOFND_=];Z'U!+ P04    " !R:%):O,/0-B 7  !(5@  $0   &0Y
M,C4V-3=D97@Y.3$N:'1M[5QI<QLWD_[.*OX'%-]*2JHB:4F.'%N254L=MO6N
MKA+E9+/?P!F01#2<F<PAF?GU^W0#F,&0U!4[>E.U3B6Q20Z 1J./IP_,WJ?K
ML]/]O4_'@Z/]=FOO^N3Z]'C_^']Z[][U-_=>F8_X_I5]0.P=7!S])@X^'EZ<
M7ER][_SZZ>3ZN".&U[^='K_O1#I6O:G2DVFQ<YYD,QEU]D6[A?&'*BY4MK]W
M=/*+>_A.A\5TYVU_6\<=(2,]B3&!&A<=7N;2/3:3V43'O2))=S;28E?8SZ.D
M*)*9^6J<Q$4OUW^JG<WZ\UC.=#3?N=8SE8MS=2>NDIG$2H/3DX_G[SL9$=G9
MWSO8/_XRU2-="-JQV'MUL+_WZG+?(\";?0NS+]"S1$YG_\=XE*>[- LV?M\^
M5HPC1F'$R=E',;PZ?-^9O-O:?K/]\V1C:_/MUN;V]L:;GS:W^K^G$]K$]?O.
MZ<7'"\.L)L'>2DSQMV)9P&?8V3^4(QFIHI#B0"=B$,=)&0<8\3D-9:%"<0@Q
MT(&,Q)'$,X_PX5L3=Z1F29P7F2QT/!%'2J4JIK]51%VI/,43F$0&69+G+TW@
M61D5.HV4.(E#$%1H$"/N=#$ERE0O4)&0A?B@1EDIL[D8!AH#]5@'+TZH4L3#
M_*7%:^]D_\=_;6YO[%9GUFZI,1@@@[D(,)&.2TA9D8B03U<DMRH3!68U;"RF
MF5)B>'HL4G 7D^9"Q^+HXNID*#(UTWD.EG?QF!)CG>6%.#UW3T(DIEK=DKP$
MR0R'5"@,B2$UF96:KI!QZ(T-%:P<MCU/<EWHO)IH)G5<X#^:2N+3[TDFKD&
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M/L^9U #G )=>*',0DNS.V*(S%@>:#$Z6L<*BRZN\&XLW3+<$0",$@BF2N H
M[71L0<'O.Z5N0#,I]3D)W4AE+!X0(AWHU- " WE'2@]1(W?.%.8EG1C/R(<
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M+3(P,C4P,C$X+GAS9%!+ 0(4 Q0    ( ')H4EH7  ]WK@8  (%)   5
M          "  6P#  !C86)A+3(P,C4P,C$X7VQA8BYX;6Q02P$"% ,4
M" !R:%):*SLW MX$  #\+0  %0              @ %-"@  8V%B82TR,#(U
M,#(Q.%]P<F4N>&UL4$L! A0#%     @ <FA26I$YYEH'$0  5'    \
M         ( !7@\  &0Y,C4V-3=D.&MA+FAT;5!+ 0(4 Q0    ( ')H4EJ\
MP] V(!<  $A6   1              "  9(@  !D.3(U-C4W9&5X.3DQ+FAT
7;5!+!08     !0 % $$!  #A-P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d925657d8ka_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="caba-20250218.xsd" xlink:type="simple"/>
    <context id="duration_2025-02-18_to_2025-02-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <startDate>2025-02-18</startDate>
            <endDate>2025-02-18</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-282">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-02-18_to_2025-02-18"
      id="Hidden_dei_EntityCentralIndexKey">0001759138</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-293">8-K/A</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-294">2025-02-18</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-295">CABALETTA BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-296">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-297">001-39103</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-298">82-1685768</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-299">2929 Arch Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-300">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-301">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-302">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-303">19104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-304">(267)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-305">759-3100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-306">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-307">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-308">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-309">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-310">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-311">CABA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-312">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-313">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentDescription contextRef="duration_2025-02-18_to_2025-02-18" id="ixv-168">Cabaletta Bio, Inc. (the &#x201c;Company&#x201d; or &#x201c;Cabaletta&#x201d;) filed a Current Report on Form 8-K on February&#160;18, 2025 in connection with a press release announcing new and updated clinical data from the first 10 patients dosed with resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) across the RESET clinical development program (the &#x201c;Original 8-K&#x201d;). This Amendment No.&#160;1 (&#x201c;Amendment No.&#160;1&#x201d;) to the Original 8-K is being filed to clarify that as of the data cut-off date of January&#160;8, 2025, in the RESET-Myositis trial, the first adult dermatomyositis patient was off all immunosuppressants and tapering steroids, to revise other similar statements, and to note that a revised copy of the corporate presentation has been posted to the Company&#x2019;s website and a copy of the revised press release has been furnished herewith to reflect the same, and no changes to the other information filed with the Original Form 8-K have been made.</dei:AmendmentDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
